Friday, November 9, 2012

Prize4Life Will Announce the Winners of The DREAM-Phil Bowen ALS Prediction Prize4Life Challenge (ALS Prediction Prize) Next Week

This summer, Prize4Life launched it’s DREAM-Phil Bowen ALS Prediction Prize4Life Challenge. The DREAM-Phil Bowen ALS Prediction Prize4Life Challenge was aimed at confronting a specific and basic puzzling question in ALS. While most patients are like Lou Gehrig with a rapidly progressing disease course, some patients turn out to be more like Stephen Hawking, where the disease progression is delayed. What separates the Lou Gehrigs from the Stephen Hawkings? Within the ALS patient population there is enormous variability in the progress of the disease. Some people live for many years or even decades, while others die much sooner. This makes it extremely difficult to develop new and effective treatments for this as-yet incurable disease. Solving this mystery is important, for patients and their families and for those planning clinical trials of potential new treatments. The winners of the ALS Prediction Prize may hold the key. On average, people diagnosed with ALS, a fatal disease, live about 1,000 days (around three years). Currently, there is only one FDA approved drug available for ALS patients. The drug does not improve quality of life and only extends life by about three months. We are happy to announce that Prize4Life has selected its winners of the ALS Prediction Prize. Next up we will explain how the winners were chosen.

No comments:

Post a Comment